论文部分内容阅读
目的检测原发性肺癌患者外周血PD-1淋巴细胞亚型,并进行临床随访,分析其与临床预后的关系。方法采集2015年1月至2016年11月在河南省肿瘤医院呼吸内科诊治的35例可疑原发性肺癌患者的血液学标本,并进行外周血淋巴细胞亚型分析以及PD-1表达,然后进行临床随访。结果 35例患者中,31例患者最终病理确诊为原发性肺癌(腺癌23例,鳞癌3例,小细胞肺癌5例),剩余4例患者为炎症。CD3+CD8+T细胞比例数值高、CD4+/CD8+的比值低、PD-1+/PBMC比例高的患者近期疗效越好。未发现治疗前淋巴细胞亚型比例异常患者与正常患者之间存在PFS的差异。结论在本项回顾性小样本研究中,发现原发性肺癌治疗前特定淋巴细胞亚型与近期疗效相关,尤其是PD-1+PBMC比例升高的患者近期疗效更佳。需要进一步前瞻性大样本研究验证。
Objective To detect the peripheral blood PD-1 lymphocyte subsets in patients with primary lung cancer and to investigate the relationship between PD-1 and clinical prognosis. Methods Hematological specimens from 35 patients with suspected primary lung cancer diagnosed and treated in Department of Respiratory Medicine of Henan Provincial Tumor Hospital from January 2015 to November 2016 were collected and analyzed for peripheral blood lymphocyte subtype and PD-1 expression. Clinical follow-up. Results Of the 35 patients, 31 patients were diagnosed as primary lung cancer (23 adenocarcinomas, 3 squamous cell carcinomas and 5 small cell lung carcinomas) in the final pathology. The remaining 4 patients were inflammatory. The ratio of CD3 + CD8 + T cells is high and the ratio of CD4 + / CD8 + is low. No difference in PFS was found between patients with abnormal proportion of pre-treatment lymphocyte subtypes and normal patients. Conclusions In this retrospective small sample study, it was found that the specific lymphocyte subtypes prior to treatment of primary lung cancer correlate with short-term outcomes, especially in patients with a higher proportion of PD-1 + PBMC. Need for further prospective large sample study validation.